NO320601B1 - Anvendelse av albumin til fremstilling av farmasoytiske preparater - Google Patents

Anvendelse av albumin til fremstilling av farmasoytiske preparater Download PDF

Info

Publication number: NO320601B1
Authority: NO; Norway
Prior art keywords: albumin; eye; damage; cornea; conjunctiva
Prior art date: 1996-04-19

Application number

NO19975962A

Other languages

English (en)

Norwegian (no)

Other versions

NO975962L (no

NO975962D0 (no

Inventor

Kazuo Tsubota

Original Assignee

R Tech Ueno Ltd

Kazuo Tsubota

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1996-04-19

Filing date

1997-12-18

Publication date

2005-12-27

1997-12-18 Application filed by R Tech Ueno Ltd, Kazuo Tsubota filed Critical R Tech Ueno Ltd

1997-12-18 Publication of NO975962D0 publication Critical patent/NO975962D0/no

1998-02-18 Publication of NO975962L publication Critical patent/NO975962L/no

2005-12-27 Publication of NO320601B1 publication Critical patent/NO320601B1/no

Links

102000009027 Albumins Human genes 0.000 title claims abstract description 54
108010088751 Albumins Proteins 0.000 title claims abstract description 54
238000002360 preparation method Methods 0.000 title claims description 22
239000008194 pharmaceutical composition Substances 0.000 title abstract 4
208000003556 Dry Eye Syndromes Diseases 0.000 claims abstract description 25
206010013774 Dry eye Diseases 0.000 claims abstract description 25
238000011282 treatment Methods 0.000 claims abstract description 14
238000004519 manufacturing process Methods 0.000 claims abstract description 7
239000004480 active ingredient Substances 0.000 claims abstract description 5
230000006378 damage Effects 0.000 claims description 29
210000004087 cornea Anatomy 0.000 claims description 24
210000000795 conjunctiva Anatomy 0.000 claims description 23
239000000825 pharmaceutical preparation Substances 0.000 claims description 15
239000003889 eye drop Substances 0.000 claims description 5
229940012356 eye drops Drugs 0.000 claims description 5
102000015728 Mucins Human genes 0.000 abstract description 8
108010063954 Mucins Proteins 0.000 abstract description 8
210000000981 epithelium Anatomy 0.000 abstract description 7
238000000034 method Methods 0.000 abstract description 7
230000028327 secretion Effects 0.000 abstract description 7
230000003902 lesion Effects 0.000 abstract 2
102000008100 Human Serum Albumin Human genes 0.000 description 15
108091006905 Human Serum Albumin Proteins 0.000 description 15
210000004027 cell Anatomy 0.000 description 13
230000007547 defect Effects 0.000 description 13
239000000243 solution Substances 0.000 description 13
238000010186 staining Methods 0.000 description 13
238000009472 formulation Methods 0.000 description 11
239000000203 mixture Substances 0.000 description 11
238000012360 testing method Methods 0.000 description 9
239000000607 artificial tear Substances 0.000 description 8
108090000623 proteins and genes Proteins 0.000 description 8
208000024891 symptom Diseases 0.000 description 8
230000000694 effects Effects 0.000 description 7
GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 7
239000003921 oil Substances 0.000 description 7
229930187593 rose bengal Natural products 0.000 description 7
AZJPTIGZZTZIDR-UHFFFAOYSA-L rose bengal Chemical compound [K+].[K+].[O-]C(=O)C1=C(Cl)C(Cl)=C(Cl)C(Cl)=C1C1=C2C=C(I)C(=O)C(I)=C2OC2=C(I)C([O-])=C(I)C=C21 AZJPTIGZZTZIDR-UHFFFAOYSA-L 0.000 description 7
229940081623 rose bengal Drugs 0.000 description 7
STRXNPAVPKGJQR-UHFFFAOYSA-N rose bengal A Natural products O1C(=O)C(C(=CC=C2Cl)Cl)=C2C21C1=CC(I)=C(O)C(I)=C1OC1=C(I)C(O)=C(I)C=C21 STRXNPAVPKGJQR-UHFFFAOYSA-N 0.000 description 7
208000021386 Sjogren Syndrome Diseases 0.000 description 6
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
102000016359 Fibronectins Human genes 0.000 description 4
108010067306 Fibronectins Proteins 0.000 description 4
OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 4
LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 4
RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 4
239000002953 phosphate buffered saline Substances 0.000 description 4
235000018102 proteins Nutrition 0.000 description 4
102000004169 proteins and genes Human genes 0.000 description 4
239000000126 substance Substances 0.000 description 4
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 3
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
206010020751 Hypersensitivity Diseases 0.000 description 3
208000009319 Keratoconjunctivitis Sicca Diseases 0.000 description 3
208000026935 allergic disease Diseases 0.000 description 3
230000007815 allergy Effects 0.000 description 3
239000003085 diluting agent Substances 0.000 description 3
239000003814 drug Substances 0.000 description 3
229920002674 hyaluronan Polymers 0.000 description 3
229960003160 hyaluronic acid Drugs 0.000 description 3
244000005700 microbiome Species 0.000 description 3
238000005215 recombination Methods 0.000 description 3
230000006798 recombination Effects 0.000 description 3
239000003381 stabilizer Substances 0.000 description 3
208000005494 xerophthalmia Diseases 0.000 description 3
SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical compound FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 description 2
241000894006 Bacteria Species 0.000 description 2
241000537222 Betabaculovirus Species 0.000 description 2
229920001287 Chondroitin sulfate Polymers 0.000 description 2
WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 2
206010015958 Eye pain Diseases 0.000 description 2
241000233866 Fungi Species 0.000 description 2
108010024636 Glutathione Proteins 0.000 description 2
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
102000014150 Interferons Human genes 0.000 description 2
108010050904 Interferons Proteins 0.000 description 2
206010023644 Lacrimation increased Diseases 0.000 description 2
NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
NCXMLFZGDNKEPB-UHFFFAOYSA-N Pimaricin Natural products OC1C(N)C(O)C(C)OC1OC1C=CC=CC=CC=CCC(C)OC(=O)C=CC2OC2CC(O)CC(O)(CC(O)C2C(O)=O)OC2C1 NCXMLFZGDNKEPB-UHFFFAOYSA-N 0.000 description 2
WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
241000700605 Viruses Species 0.000 description 2
239000002253 acid Substances 0.000 description 2
239000003732 agents acting on the eye Substances 0.000 description 2
239000002647 aminoglycoside antibiotic agent Substances 0.000 description 2
230000002421 anti-septic effect Effects 0.000 description 2
229940064004 antiseptic throat preparations Drugs 0.000 description 2
229960000686 benzalkonium chloride Drugs 0.000 description 2
CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 2
210000004369 blood Anatomy 0.000 description 2
239000008280 blood Substances 0.000 description 2
239000006172 buffering agent Substances 0.000 description 2
239000002738 chelating agent Substances 0.000 description 2
229960004926 chlorobutanol Drugs 0.000 description 2
229940059329 chondroitin sulfate Drugs 0.000 description 2
230000007797 corrosion Effects 0.000 description 2
238000005260 corrosion Methods 0.000 description 2
230000003013 cytotoxicity Effects 0.000 description 2
231100000135 cytotoxicity Toxicity 0.000 description 2
229940079593 drug Drugs 0.000 description 2
FAOZLTXFLGPHNG-KNAQIMQKSA-N fluorometholone Chemical compound C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@]2(F)[C@@H](O)C[C@]2(C)[C@@](O)(C(C)=O)CC[C@H]21 FAOZLTXFLGPHNG-KNAQIMQKSA-N 0.000 description 2
229960001048 fluorometholone Drugs 0.000 description 2
229960003180 glutathione Drugs 0.000 description 2
238000010438 heat treatment Methods 0.000 description 2
208000015181 infectious disease Diseases 0.000 description 2
229940079322 interferon Drugs 0.000 description 2
239000007951 isotonicity adjuster Substances 0.000 description 2
206010023332 keratitis Diseases 0.000 description 2
201000010666 keratoconjunctivitis Diseases 0.000 description 2
230000004317 lacrimation Effects 0.000 description 2
239000002609 medium Substances 0.000 description 2
229960003255 natamycin Drugs 0.000 description 2
NCXMLFZGDNKEPB-FFPOYIOWSA-N natamycin Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C[C@@H](C)OC(=O)/C=C/[C@H]2O[C@@H]2C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 NCXMLFZGDNKEPB-FFPOYIOWSA-N 0.000 description 2
229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 2
229940125702 ophthalmic agent Drugs 0.000 description 2
230000001717 pathogenic effect Effects 0.000 description 2
230000000149 penetrating effect Effects 0.000 description 2
230000001105 regulatory effect Effects 0.000 description 2
230000035807 sensation Effects 0.000 description 2
210000002966 serum Anatomy 0.000 description 2
230000001502 supplementing effect Effects 0.000 description 2
239000004094 surface-active agent Substances 0.000 description 2
238000002054 transplantation Methods 0.000 description 2
OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
241000283707 Capra Species 0.000 description 1
GHXZTYHSJHQHIJ-UHFFFAOYSA-N Chlorhexidine Chemical class C=1C=C(Cl)C=CC=1NC(N)=NC(N)=NCCCCCCN=C(N)N=C(N)NC1=CC=C(Cl)C=C1 GHXZTYHSJHQHIJ-UHFFFAOYSA-N 0.000 description 1
206010010744 Conjunctivitis allergic Diseases 0.000 description 1
206010011013 Corneal erosion Diseases 0.000 description 1
208000028006 Corneal injury Diseases 0.000 description 1
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
229920002307 Dextran Polymers 0.000 description 1
ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 description 1
241000588724 Escherichia coli Species 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
239000004471 Glycine Substances 0.000 description 1
102000003886 Glycoproteins Human genes 0.000 description 1
108090000288 Glycoproteins Proteins 0.000 description 1
208000003623 Hypoalbuminemia Diseases 0.000 description 1
QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
229930195725 Mannitol Natural products 0.000 description 1
241001465754 Metazoa Species 0.000 description 1
101000844719 Mus musculus Deleted in malignant brain tumors 1 protein Proteins 0.000 description 1
206010067776 Ocular pemphigoid Diseases 0.000 description 1
229930040373 Paraformaldehyde Natural products 0.000 description 1
206010036346 Posterior capsule opacification Diseases 0.000 description 1
240000004808 Saccharomyces cerevisiae Species 0.000 description 1
206010049771 Shock haemorrhagic Diseases 0.000 description 1
206010042033 Stevens-Johnson syndrome Diseases 0.000 description 1
231100000168 Stevens-Johnson syndrome Toxicity 0.000 description 1
229930006000 Sucrose Natural products 0.000 description 1
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
HEUMNKZPHGRBKR-UHFFFAOYSA-N [Na].[Cr] Chemical compound [Na].[Cr] HEUMNKZPHGRBKR-UHFFFAOYSA-N 0.000 description 1
230000002159 abnormal effect Effects 0.000 description 1
238000004378 air conditioning Methods 0.000 description 1
235000004279 alanine Nutrition 0.000 description 1
208000002205 allergic conjunctivitis Diseases 0.000 description 1
229910000147 aluminium phosphate Inorganic materials 0.000 description 1
235000001014 amino acid Nutrition 0.000 description 1
150000001413 amino acids Chemical class 0.000 description 1
210000001691 amnion Anatomy 0.000 description 1
238000004458 analytical method Methods 0.000 description 1
208000024998 atopic conjunctivitis Diseases 0.000 description 1
125000005501 benzalkonium group Chemical class 0.000 description 1
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
210000001124 body fluid Anatomy 0.000 description 1
239000010839 body fluid Substances 0.000 description 1
230000037396 body weight Effects 0.000 description 1
KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 1
239000004327 boric acid Substances 0.000 description 1
238000004364 calculation method Methods 0.000 description 1
239000002775 capsule Substances 0.000 description 1
150000001720 carbohydrates Chemical class 0.000 description 1
239000004359 castor oil Substances 0.000 description 1
235000019438 castor oil Nutrition 0.000 description 1
238000004113 cell culture Methods 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
201000010002 cicatricial pemphigoid Diseases 0.000 description 1
229910017052 cobalt Inorganic materials 0.000 description 1
239000010941 cobalt Substances 0.000 description 1
GUTLYIVDDKVIGB-UHFFFAOYSA-N cobalt atom Chemical compound [Co] GUTLYIVDDKVIGB-UHFFFAOYSA-N 0.000 description 1
230000001276 controlling effect Effects 0.000 description 1
201000007717 corneal ulcer Diseases 0.000 description 1
229960000265 cromoglicic acid Drugs 0.000 description 1
210000004748 cultured cell Anatomy 0.000 description 1
230000007812 deficiency Effects 0.000 description 1
238000011161 development Methods 0.000 description 1
235000005911 diet Nutrition 0.000 description 1
230000037213 diet Effects 0.000 description 1
150000002016 disaccharides Chemical class 0.000 description 1
VLARUOGDXDTHEH-UHFFFAOYSA-L disodium cromoglycate Chemical compound [Na+].[Na+].O1C(C([O-])=O)=CC(=O)C2=C1C=CC=C2OCC(O)COC1=CC=CC2=C1C(=O)C=C(C([O-])=O)O2 VLARUOGDXDTHEH-UHFFFAOYSA-L 0.000 description 1
239000002552 dosage form Substances 0.000 description 1
238000001962 electrophoresis Methods 0.000 description 1
210000002919 epithelial cell Anatomy 0.000 description 1
210000003560 epithelium corneal Anatomy 0.000 description 1
150000002148 esters Chemical class 0.000 description 1
238000011156 evaluation Methods 0.000 description 1
238000001704 evaporation Methods 0.000 description 1
230000008020 evaporation Effects 0.000 description 1
210000000744 eyelid Anatomy 0.000 description 1
238000000684 flow cytometry Methods 0.000 description 1
MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
238000005194 fractionation Methods 0.000 description 1
210000004602 germ cell Anatomy 0.000 description 1
239000008103 glucose Substances 0.000 description 1
150000004676 glycans Chemical class 0.000 description 1
229940047135 glycate Drugs 0.000 description 1
ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
239000001963 growth medium Substances 0.000 description 1
230000000415 inactivating effect Effects 0.000 description 1
238000010348 incorporation Methods 0.000 description 1
239000007924 injection Substances 0.000 description 1
238000002347 injection Methods 0.000 description 1
230000003993 interaction Effects 0.000 description 1
238000011835 investigation Methods 0.000 description 1
239000000594 mannitol Substances 0.000 description 1
235000010355 mannitol Nutrition 0.000 description 1
HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
239000011259 mixed solution Substances 0.000 description 1
150000002772 monosaccharides Chemical class 0.000 description 1
239000002674 ointment Substances 0.000 description 1
229920002866 paraformaldehyde Polymers 0.000 description 1
239000002504 physiological saline solution Substances 0.000 description 1
239000006187 pill Substances 0.000 description 1
229920001282 polysaccharide Polymers 0.000 description 1
239000005017 polysaccharide Substances 0.000 description 1
239000001103 potassium chloride Substances 0.000 description 1
235000011164 potassium chloride Nutrition 0.000 description 1
239000000843 powder Substances 0.000 description 1
230000002265 prevention Effects 0.000 description 1
239000000047 product Substances 0.000 description 1
239000002994 raw material Substances 0.000 description 1
150000003839 salts Chemical class 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
229940037001 sodium edetate Drugs 0.000 description 1
230000006641 stabilisation Effects 0.000 description 1
238000011105 stabilization Methods 0.000 description 1
230000000087 stabilizing effect Effects 0.000 description 1
-1 sterilisers Substances 0.000 description 1
239000003206 sterilizing agent Substances 0.000 description 1
239000005720 sucrose Substances 0.000 description 1
150000005846 sugar alcohols Chemical class 0.000 description 1
239000006228 supernatant Substances 0.000 description 1
239000000829 suppository Substances 0.000 description 1
238000001356 surgical procedure Methods 0.000 description 1
239000000725 suspension Substances 0.000 description 1
230000009885 systemic effect Effects 0.000 description 1
239000003826 tablet Substances 0.000 description 1
210000001519 tissue Anatomy 0.000 description 1
235000013311 vegetables Nutrition 0.000 description 1
230000000007 visual effect Effects 0.000 description 1
239000000811 xylitol Substances 0.000 description 1
235000010447 xylitol Nutrition 0.000 description 1
HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
229960002675 xylitol Drugs 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/38—Albumins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/04—Artificial tears; Irrigation solutions

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Immunology (AREA)
Zoology (AREA)
Epidemiology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Gastroenterology & Hepatology (AREA)
Ophthalmology & Optometry (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicinal Preparation (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)

NO19975962A 1996-04-19 1997-12-18 Anvendelse av albumin til fremstilling av farmasoytiske preparater NO320601B1 (no)

Applications Claiming Priority (5)

Application Number	Priority Date	Filing Date	Title
JP9809096		1996-04-19
JP10686696		1996-04-26
US75292896A	1996-11-21	1996-11-21
US75294196A	1996-11-21	1996-11-21
PCT/JP1997/001329 WO1997039769A1 (en)	1996-04-19	1997-04-17	Drug composition comprising albumin as active ingredient

Publications (3)

Publication Number	Publication Date
NO975962D0 NO975962D0 (no)	1997-12-18
NO975962L NO975962L (no)	1998-02-18
NO320601B1 true NO320601B1 (no)	2005-12-27

Family

ID=27468604

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO19975962A NO320601B1 (no)	1996-04-19	1997-12-18	Anvendelse av albumin til fremstilling av farmasoytiske preparater

Country Status (11)

Country	Link
US (2)	US6043213A (de)
EP (1)	EP0834320B1 (de)
JP (1)	JP3058920B2 (de)
KR (1)	KR100455475B1 (de)
CN (1)	CN1124158C (de)
AT (1)	ATE274918T1 (de)
CA (1)	CA2225398C (de)
DE (1)	DE69730476T2 (de)
ES (1)	ES2227684T3 (de)
NO (1)	NO320601B1 (de)
WO (1)	WO1997039769A1 (de)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA2373166C (en) *	1999-07-28	2009-05-19	Morinaga Milk Industry Co., Ltd.	Antiulcer agent
GB0019378D0 (en) *	2000-08-07	2000-09-27	Saugstad Ola D	Method
ES2300398T3 (es) *	2001-04-26	2008-06-16	R-Tech Ueno, Ltd.	Uso de albumina en combinacion con factores de crecimiento para inhibir la apoptosis.
US20030211043A1 (en) *	2001-09-28	2003-11-13	Korb Donald R.	Eye treatment
US20060234907A1 (en) *	2004-02-13	2006-10-19	Werner Gehringer	Albumin solution and process for the production thereof
US20050202097A1 (en) *	2004-03-12	2005-09-15	Melbj Holdings, Llc, Florida	Lubricant for the ocular surface
US8455016B2 (en)	2004-03-12	2013-06-04	Melbj Holdings, Llc	Treatment for meibomian gland dysfunction or obstruction
US7189697B2 (en) *	2004-04-13	2007-03-13	Trustees Of Tufts College	Compositions and uses of a galectin for treatment of dry eye syndrome
US20060232060A1 (en) *	2005-04-13	2006-10-19	Assignee1	Pressure sensitive packing laminate overlay form combination and method of using same
WO2007033020A2 (en) *	2005-09-13	2007-03-22	Bausch & Lomb Incorporated	Ophthalmic formulation for treatment of dry eye
WO2008133928A2 (en) *	2007-04-27	2008-11-06	The Gi Company, Inc.	Mucin glycoproteins and their use for treatment of epithelial lesions and mucin dependent disorders
RU2010151453A (ru) *	2008-05-15	2012-06-20	Р-Тек Уено, Лтд. (Jp)	Фармацевтическая композиция для лечения сухости глаз и/или повреждения конъюнктивы и роговицы
KR101422571B1 (ko)	2009-10-13	2014-07-24	삼성전자 주식회사	받침대 및 이를 구비한 세탁기
AU2010323566B2 (en) *	2009-11-27	2014-06-05	R-Tech Ueno, Ltd.	Method for screening drug efficacious in treating dry eye and/or keratoconjunctival disorders and pharmaceutical composition obtained thereby
AU2013203609B2 (en) *	2009-11-27	2014-08-21	R-Tech Ueno, Ltd.	Method for screening drug efficacious in treating dry eye and/or keratoconjunctival disorders and pharmaceutical composition obtained thereby
AU2011347237A1 (en) *	2010-12-21	2013-07-11	Recopharma Ab	Tear substitutes
US11730716B2 (en)	2014-05-08	2023-08-22	Kiora Pharmaceuticals Gmbh	Compounds for treating ophthalmic diseases and disorders
DE102015205293A1 (de) *	2015-03-24	2016-09-29	Marc Schrott	Verfahren zur Herstellung von Augentropfen
US11071706B2 (en) *	2016-04-01	2021-07-27	Biocoz Global Korea Corp.	Cosmetic composition containing, as active ingredient, albumin, hyaluronic acid or collagen in cell culture medium
WO2019170848A1 (en) *	2018-03-09	2019-09-12	Panoptes Pharma Ges.M.B.H.	Ophthalmic formulation
KR20210038636A (ko)	2018-07-27	2021-04-07	존슨 앤드 존슨 서지컬 비전, 인코포레이티드	눈 치료용 조성물 및 방법
US10966948B2 (en)	2019-07-23	2021-04-06	Johnson & Johnson Surgical Vision, Inc.	Compositions and methods for treating the eye
US20200030226A1 (en)	2018-07-27	2020-01-30	Johnson & Johnson Consumer Inc.	Botanical and bacterial extracts displaying retinol-like activity
US11969454B2 (en)	2019-11-19	2024-04-30	Johnson & Johnson Surgical Vision, Inc.	Compositions and methods for treating the eye
US12161777B2 (en)	2020-07-02	2024-12-10	Davol Inc.	Flowable hemostatic suspension
US11739166B2 (en)	2020-07-02	2023-08-29	Davol Inc.	Reactive polysaccharide-based hemostatic agent
JP2024500994A (ja)	2020-12-28	2024-01-10	デボル，インコーポレイテッド	タンパク質及び多官能化変性ポリエチレングリコール系架橋剤を含む反応性乾燥粉末状止血用材料
EP4558516B1 (de)	2022-07-18	2025-08-13	Yeda Research and Development Co. Ltd	Albumin protein varianten, deren herstellung und verwendungen

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPS57126422A (en) *	1981-01-29	1982-08-06	Green Cross Corp:The	Stabilizing method of lysozyme pharmaceutical
JPS61103836A (ja) *	1984-10-24	1986-05-22	Green Cross Corp:The	フイブロネクチン製剤
CA1263606A (en) *	1985-05-29	1989-12-05	Jeffrey P. Gilbard	Non-toxic opthalmic preparations
JPS6391331A (ja) *	1986-10-03	1988-04-22	Senjiyu Seiyaku Kk	眼科用水性組成物
KR920700691A (ko) *	1989-04-04	1992-08-10	존.에프.맥인티리	상처부위, 절개부위, 찰과상 부위에 치료제의 투여에 대한 리포좀(liposomes)의 용도
US5174988A (en) *	1989-07-27	1992-12-29	Scientific Development & Research, Inc.	Phospholipid delivery system
JPH05310592A (ja) *	1992-05-11	1993-11-22	Nichirei Corp	創傷治療剤及び医薬製剤
JPH06271478A (ja) *	1993-03-23	1994-09-27	Otsuka Pharmaceut Co Ltd	ドライアイ治療剤
EP0637450A3 (de) *	1993-08-04	1995-04-05	Collagen Corp	Verfahren und Zusammensetzung zur Wiederbelebung von Nerbgewebe.
US6013628A (en) *	1994-02-28	2000-01-11	Regents Of The University Of Minnesota	Method for treating conditions of the eye using polypeptides

1997
- 1997-04-17 CA CA002225398A patent/CA2225398C/en not_active Expired - Fee Related
- 1997-04-17 EP EP97917418A patent/EP0834320B1/de not_active Expired - Lifetime
- 1997-04-17 US US08/981,229 patent/US6043213A/en not_active Expired - Lifetime
- 1997-04-17 CN CN97190706A patent/CN1124158C/zh not_active Expired - Fee Related
- 1997-04-17 KR KR1019970709546A patent/KR100455475B1/ko not_active Expired - Fee Related
- 1997-04-17 ES ES97917418T patent/ES2227684T3/es not_active Expired - Lifetime
- 1997-04-17 WO PCT/JP1997/001329 patent/WO1997039769A1/ja not_active Ceased
- 1997-04-17 DE DE69730476T patent/DE69730476T2/de not_active Expired - Lifetime
- 1997-04-17 JP JP9537910A patent/JP3058920B2/ja not_active Expired - Fee Related
- 1997-04-17 AT AT97917418T patent/ATE274918T1/de not_active IP Right Cessation
- 1997-12-18 NO NO19975962A patent/NO320601B1/no not_active IP Right Cessation
1999
- 1999-11-29 US US09/450,008 patent/US6159930A/en not_active Expired - Lifetime

Also Published As

Publication number	Publication date
EP0834320A1 (de)	1998-04-08
US6159930A (en)	2000-12-12
DE69730476D1 (de)	2004-10-07
US6043213A (en)	2000-03-28
CN1124158C (zh)	2003-10-15
CA2225398A1 (en)	1997-10-30
NO975962L (no)	1998-02-18
KR19990028235A (ko)	1999-04-15
JP3058920B2 (ja)	2000-07-04
EP0834320B1 (de)	2004-09-01
WO1997039769A1 (en)	1997-10-30
NO975962D0 (no)	1997-12-18
EP0834320A4 (de)	2000-11-22
KR100455475B1 (ko)	2004-12-17
CA2225398C (en)	2008-07-15
CN1195296A (zh)	1998-10-07
DE69730476T2 (de)	2005-11-17
ATE274918T1 (de)	2004-09-15
ES2227684T3 (es)	2005-04-01

Legal Events

Date	Code	Title	Description
2016-11-28	MM1K	Lapsed by not paying the annual fees

Publication	Publication Date	Title
NO320601B1 (no)	2005-12-27	Anvendelse av albumin til fremstilling av farmasoytiske preparater
JPWO1997039769A1 (ja)	1998-10-06	アルブミンを有効成分とする医薬組成物
KR101401353B1 (ko)	2014-05-29	점안약의 형태로 안구 사용을 위한 생리적 보조제 또는의약품의 제조를 위한 ｌ-카르니틴 또는 알카노일ｌ-카르니틴의 용도
KR20090040404A (ko)	2009-04-24	고안압증 치료를 위한 항분비 인자의 용도
US20110065642A1 (en)	2011-03-17	Pharmaceutical composition for the treatment of dry eye and/or corneal and conjunctival lesion
US9345749B2 (en)	2016-05-24	Method of treating intraoccular tissue pathologies with nerve growth factor
KR20010041337A (ko)	2001-05-15	각막 상피 장애증 치료제
AU2006260184B2 (en)	2011-05-12	Prophylactic or therapeutic agent for corneal/conjunctival disease
MXPA03011613A (es)	2004-07-01	Composicion oftalmica que contiene n-acetil-cisteina para el trtamiento de sindrome de ojo seco.
Nelson et al.	1994	Evaluation of a physiological tear substitute in patients with keratoconjunctivitis sicca
US10406208B2 (en)	2019-09-10	Composition containing thymosin beta 4, and pharmaceutical formulation comprising same
JPH06271478A (ja)	1994-09-27	ドライアイ治療剤
JP2019525923A (ja)	2019-09-12	ドライアイ症候群を治療する方法
AU725508B2 (en)	2000-10-12	Pharmaceutical composition comprising albumin as an active ingredient
IE54426B1 (en)	1989-10-11	Therapeutic composition based inosine monophosphate for the treatment of eye accommodation disorders
US20250161403A1 (en)	2025-05-22	Peptides and methods of use thereof in treating ocular disorders
RU2149610C1 (ru)	2000-05-27	Способ лечения вирусных кератоконъюнктивитов, осложненных дефицитом иммуноглобулина а.
JPH09100233A (ja)	1997-04-15	角膜保護剤
HK1156536A (en)	2012-06-15	Pharmaceutical composition for treatment of dry eye and/or corneal/conjunctival disorders
HK1152888A (en)	2012-03-16	Pharmaceutical composition for treatment of dry eye and/or corneal/conjunctival disorders